Eli Lilly (LLY, Financial) announced that its weight-loss drug, Zepbound, demonstrated superior results in a head-to-head trial against Novo Nordisk’s (NVO) Wegovy. Participants treated with Zepbound lost an average of 20% of their body weight, approximately 50 pounds, over 72 weeks, compared to a 14% reduction for those on Wegovy. Both drugs showed similar gastrointestinal side effects.
Complete study results will be published in a peer-reviewed journal and presented at next year’s medical conferences. Despite Novo Nordisk’s pioneering role in GLP-1 obesity drugs, Lilly’s findings provide a competitive edge in the market, projected to reach $130 billion by the decade’s end. Novo Nordisk is testing CagriSema, aiming for a 25% weight reduction.
